You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 9,012,606

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,012,606
Title:In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same
Abstract: The present invention relates to a fusion protein or peptide, the in vivo half-life of which is increased by maintaining in vivo sustained release, and to a method for increasing in vivo half-life using same. A fusion protein or peptide according to the present invention has excellent in vivo stability by binding a physiologically active protein or physiologically active peptide to an alpha-1 antitrypsin or alpha-1 antitrypsin mutant with one or more amino acids mutated to maintain the in vivo sustained release and to significantly increase the half-life thereof in blood (T1/2) compared to an inherent physiologically active protein or physiologically active peptide. Thus, a fusion protein or peptide according to the present invention can be useful in developing a sustained-release preparation of a protein or peptide drug.
Inventor(s): Chung; Hye-Shin (Daejeon, KR), Yoo; Seung Bum (Daejeon, KR), Lee; Sang Mee (Daejeon, KR)
Assignee: Alteogen, Inc. (Daejeon, KR)
Application Number:13/265,775
Patent Claims:see list of patent claims

Details for Patent 9,012,606

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 004 1975-06-26   Start Trial Alteogen, Inc. (Daejeon, KR) 2029-04-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 006 1975-06-26   Start Trial Alteogen, Inc. (Daejeon, KR) 2029-04-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 007 1975-06-26   Start Trial Alteogen, Inc. (Daejeon, KR) 2029-04-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 009 1975-06-26   Start Trial Alteogen, Inc. (Daejeon, KR) 2029-04-22 RX search
Ferring CHORIONIC GONADOTROPIN gonadotropin, chorionic INJECTABLE;INJECTION 017016 010 1975-06-26   Start Trial Alteogen, Inc. (Daejeon, KR) 2029-04-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Merck
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.